Literature DB >> 23821591

Neuroprotective effects of α-ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in mice.

R Satpute1, V Lomash, M Kaushal, R Bhattacharya.   

Abstract

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin associated with drug abuse and causes permanent symptoms of Parkinson's disease (PD) by destroying dopaminergic neurons in the substantia nigra of the brain. In the present study, the neuroprotective effects of two carboxylic acid compounds, viz. alpha-ketoglutarate (A-KG), a Kreb's cycle intermediate and ethyl pyruvate (EP), a lipid-soluble analogue of pyruvate, were evaluated against MPTP intoxication in mice and compared with madopar (MD; combination of levodopa plus benserazide), a standard drug. Animals received oral treatment of A-KG (500 mg/kg), EP (100 mg/kg) or MD (5 mg/kg) daily for 5 days followed by intraperitoneal administration of MPTP (20 mg/kg) and posttreatment (+10 min) of A-KG, EP or MD daily for the remaining 5 days. MPTP caused the inhibition of complex I of electron transport chain accompanied by oxidative stress in the brain. It also caused cytotoxicity in the midbrain region as characterized by histology and immunohistochemistry. Treatments of A-KG and EP were found to resolve the loss of motor coordination, oxidative stress, diminished complex I activity and tyrosine hydroxylase-positive neurons in midbrain. A-KG and EP also regressed the histological damage in the brain and minimized the accumulation of alpha-synuclein in the midbrain region. The data suggest that A-KG and EP which are nontoxic carboxylic acid compounds could be of potential therapeutic value in the treatment of PD.

Entities:  

Keywords:  MPTP; alpha-ketoglutarate; ethyl pyruvate; madopar; neurotoxicity; parkinsonism

Mesh:

Substances:

Year:  2013        PMID: 23821591     DOI: 10.1177/0960327112468172

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  6 in total

1.  Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.

Authors:  Vedad Delic; Jeddidiah W D Griffin; Sandra Zivkovic; Yumeng Zhang; Tam-Anh Phan; Henry Gong; Dale Chaput; Christian Reynes; Vinh B Dinh; Josean Cruz; Eni Cvitkovic; Devon Placides; Ernide Frederic; Hamed Mirzaei; Stanley M Stevens; Umesh Jinwal; Daniel C Lee; Patrick C Bradshaw
Journal:  Neuromolecular Med       Date:  2017-06-15       Impact factor: 3.843

2.  Energy substrates protect hippocampus against endogenous glutamate-mediated neurodegeneration in awake rats.

Authors:  Citlalli Netzahualcoyotzi; Ricardo Tapia
Journal:  Neurochem Res       Date:  2014-05-01       Impact factor: 3.996

3.  Degeneration of spinal motor neurons by chronic AMPA-induced excitotoxicity in vivo and protection by energy substrates.

Authors:  Citlalli Netzahualcoyotzi; Ricardo Tapia
Journal:  Acta Neuropathol Commun       Date:  2015-05-14       Impact factor: 7.801

4.  Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease.

Authors:  Rutong Ren; Chunyan Shi; Jing Cao; Yi Sun; Xin Zhao; Yongfei Guo; Chen Wang; Hui Lei; Hanjie Jiang; Nuramatjan Ablat; Jiamin Xu; Wan Li; Yingcong Ma; Xianrong Qi; Min Ye; Xiaoping Pu; Hongbin Han
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

Review 5.  Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

Review 6.  NADPH and Mitochondrial Quality Control as Targets for a Circadian-Based Fasting and Exercise Therapy for the Treatment of Parkinson's Disease.

Authors:  William M Curtis; William A Seeds; Mark P Mattson; Patrick C Bradshaw
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.